Since the VEGF and PDGF pathways are critical in gliomas, they selected vandetanib, an inhibitor of both VEGFR-2 and EGFR [144] and dasatinib, an inhibitor of PDGFR [145] Twenty-five children (aged 18 months to 20 years) with newly diagnosed DIPG were enrolled to evaluate the safety, MTD, pharmacokinetics, and pharmacodynamics of this combination administered during and after radiotherapy. The gene discussed is EGFR; the disease is glioma.